期刊文献+

乳腺导管内癌临床特点与外科治疗方式的研究 被引量:1

Research on the clinical characteristics and surgical treatment of ductal carcinoma in situ
原文传递
导出
摘要 目的探讨乳腺导管内癌(DCIS)临床特点与外科治疗方式的选择。方法回顾性分析我院2001年1月至2010年12月57例DCIS患者,总结其临床特点、病理特征与外科手术方式等,术后随访有无局部复发或远处转移等情况,探讨该病临床特点、如何选择恰当的外科治疗方式。结果在相同术后辅助治疗的前提下,保乳手术与传统的乳腺癌改良根治术对患者的术后预后情况影响差异无统计学意义(P>0.05);在相同手术方式前提下,综合治疗方案可明显改善患者预后(P<0.05)。结论 DCIS综合治疗效果确切,明显优于单纯手术治疗,可显著减少术后局部复发或远处转移;保乳手术在保留乳腺外形、增强患者自信心等优点基础上还可获得与传统乳腺癌改良根治术相同的预后效果。 Objective To explore the clinical characteristics and surgical treatment options of ductal carcinoma in situ.Methods We retrospectively analysed 57 intraductal carcinoma patients from January 2001 to December 2010,summarizing its clinical characteristics,pathological characteristics and surgical methods etc,following-up local recurrence or distant metastasis,discussing the clinical characteristics and choosing appropriate surgical interventions.Results In the same postoperative adjuvant treatments,breast-conserving surgery and traditional modified radical mastectomy for improving prognosis had no statistically significant difference(P>0.05).In the same operation method premise,comprehensive treatment can significantly improve the prognosis of patients(P<0.05).Conclusions The effect of comprehensive treatments of ductal carcinoma in situ is obviously better than simple surgery,markedly reducing postoperative local recurrence and distant metastasis;breast-conserving operation,which could retain breast appearance and enhance patients,confidence,can obtain the same outcome effect as traditional modified radical mastectomy.
出处 《中华临床医师杂志(电子版)》 CAS 2011年第12期3421-3426,共6页 Chinese Journal of Clinicians(Electronic Edition)
关键词 乳腺肿瘤 疾病特征 外科手术 综合疗法 Breast neoplasms Disease attributes Surgical procedures,operative Combined modality therapy
  • 相关文献

参考文献17

  • 1杨光,张祥宏,赵俊京,刘秀健,李智岗,王小玲,严霞,张志刚.乳腺癌钼靶X线微钙化与癌细胞ER、PR表达关系的研究[J].实用放射学杂志,2006,22(5):587-591. 被引量:30
  • 2左文述,路平华.乳腺导管内癌及小叶原位癌的治疗策略[J].中国肿瘤临床,2002,29(5):376-380. 被引量:7
  • 3Climent F,Soler MT,Catala I et al.Breast Cancer Onco Guia:surgical pathology report guidelines. Clin Transl Oncol . 2010
  • 4Ajisaka H,Tsugawa K,Noguch M,et al.Histological subtypes of ductal carcinoma in situ of the breast. Breast Cancer . 2002
  • 5Innos K,Horn-Ross PL.Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Research . 2008
  • 6Meijnen P,Oldenburg HS,Peterse JL,et al.Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Annals of Surgical Oncology . 2008
  • 7Wishart GC,Pitsinis V.New technological developments in the diagnosis and surgical management of breast cancer. Hell J of Surg . 2010
  • 8Takács T,Paszt A,Szentpáli K,et al.Importance of sentinel lymph node biopsy in surgical therapy of in situ breast cancer. Pathology and Oncology Research . 2009
  • 9Kanemaki Y,Kurihara Y,Okamoto K,et al.Ductal carcinoma in situ:correlations between high-resolution magnetic resonance imaging and histo-pathology. Radiation Medicine . 2007
  • 10Goyal A.Management of the axilla in patients with breast cancer. Indian Journal of Surgery . 2009

二级参考文献47

  • 1[1]Sakorafas GH, Tsiotou AG. Ductal carcinoma in situ (DCIS)of the breast: evolving perspectives. Cancer Treat Rev, 2000,26(2): 103~125
  • 2[2]Fisher ER, Dignam J, Tan-Chiu-E, et al. Pathologic tindings from the National Surgical Adjuvant Breast Project (NSABP)eight-year update of Protocol B-17: intraductal carcinoma.Cancer, 1999, 86(3): 429~438
  • 3[3]Leal CB, Schmitt FC, Bento MJ, et al. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone re ceptors, p53, and c-erbB-2 protein. Cancer, 1995, 75(8):2123 ~2131
  • 4[4]Sloane JP, Amendoeira I, Apostolikas N, et al. Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. Euro pean Commission Working Group on Breast Screening Pathology. Hum Pathol, 1998, 29(10): 1056~1062
  • 5[5]Warnberg F, Nordgren H, Bergh J, et al. Ductal carcinoma in situ of the breast from a population-defined cohort: an evalu ation of new histopathological classification systems. Eur J Cancer, 1999, 35(5): 714~720
  • 6[6]Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol,1994, 11(3): 167~180
  • 7[7]Wells WA, Carney PA, Eliassen MS, et al. Pathologists' a greement with experts and reproducibility of breast ductal car cinoma~in~situ classification schemes. Am J Surg Pathol,2000, 24(5): 651~659
  • 8[8]Kanthan R, Xiang J, Magliocco AM. p53, ErbB2, and TAG 72 expression in the specrum of ductal carcinoma in situ of the breast classified by the Van Nuys system. Arch Pathol Lab Med, 2000, 124(2): 234~239
  • 9[9]Poller DN. Pathology of ductal carcinoma in situ of the breast: current status. EurJ Surg Oncol, 2001, 27(5): 498~503
  • 10[10]Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic clas sification of breast ductal carcinoma-in-situ. Lancet, 1995, 345(8958): 1154~1157

共引文献34

同被引文献9

  • 1ChoSG,WangY,RodriguezM. Haploinsufficiencyintheprome-tastasisKiss1receptorGpr54delaysbreasttumorinitiation,progres-sion,andlungmetastasis[J].Cancer Research,2011.6535-6546.
  • 2ZikanM,BohmJ,PavlistaD. Comparativeanalysisoflossofhet-erozygosityandexpressionprofileinnormaltissue,DCISandinvasivebreastcancer[J].ClinTranslOncol,2011.652-655.
  • 3CoxDG,SimardJ,SinnettD. CommonvariantsoftheBRCA1wild-typeallelemodifytheriskofbreastcancerinBRCA1mutationcarriers[J].Human Molecular Genetics,2011.4732-4747.
  • 4KadouriL,BercovichD,ElimelechA. AnovelBRCA-1mutationinArabkindredfromeastJerusalemwithbreastandovariancancer[J].BMCCancer,2007.14.
  • 5DrostR,BouwmanP,RottenbergS. BRCA1RINGfunctionises-sentialfortumorsuppressionbutdispensablefortherapyresistance[J].CancerCell,2011.797-809.
  • 6ThirthagiriE,LeeSY,KangP. EvaluationofBRCA1andBRCA2mutationsandrisk-predictionmodelsinatypicalAsiancountry(Malay-sia)witharelativelylowincidenceofbreastcancer[J].BreastCancerRes,2008.59.
  • 7ChoschzickM,LebeauA,MarxAH. Overexpressionofcelldivi-sioncycle7homologisassociatedwithgeneamplificationfrequencyinbreastcancer[J].Human Pathology,2010.358-365.
  • 8易韦,文安智.BRCA_1在散发性乳腺浸润性导管癌癌组织中的表达及意义[J].山东医药,2008,48(26):82-83. 被引量:2
  • 9吕振海,贾志芳.改良根治术治疗乳腺癌2680例疗效分析[J].中华临床医师杂志(电子版),2009,3(7):93-95. 被引量:10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部